Tardive blepharospasm associated with cinnarizine use

Clinical Neuropharmacology

Volumn 29, Issue 4, 2006, Pages 187-189

  Alonso Navarro, Hortensia ^a   Jiménez Jiménez, Félix Javier ^b,c  

^a HOSPITAL VIRGEN DE LA CONCHA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c NONE   (Spain)

Author keywords

Blepharospasm; Cinnarizine; Drug induced; Focal dystonia; Side effects

Indexed keywords

BOTULINUM TOXIN; CINNARIZINE; CALCIUM CHANNEL BLOCKING AGENT;

ADULT; ANAMNESIS; ARTICLE; BLEPHAROSPASM; CASE REPORT; DISEASE ASSOCIATION; FEMALE; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; VERTIGO; CHEMICALLY INDUCED DISORDER; MIDDLE AGED;

BLEPHAROSPASM; CALCIUM CHANNEL BLOCKERS; CINNARIZINE; FEMALE; HUMANS; MIDDLE AGED;

EID: 33748755375     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wnf.0000228806.41420.22     Document Type: Article

References (25)

1. Laporte JR, Capella D. Useless drugs are not placebos: lessons from flunarizine and cinnarizine. Lancet 1986;2:853-854.
2. Martí-Massó JF, Carrera N, de la Puente E. Posible parkinsonismo por cinarizina. Med Clin (Barc) 1985;85:614-616.
3. Giménez-Roldán S, Mateo D. Cinnarizine-induced parkinsonism. Susceptibility related to aging and essential tremor. Clin Neuropharmacol 1991;14:156-164.
4. García-Ruiz PJ, García de Yébenes J, Jiménez-Jiménez FJ, et al. Parkinsonism associated with calcium channel blockers: a prospective follow-up study. Clin Neuropharmacol 1992;15:19-26.
5. Jiménez-Jiménez FJ, Ortí-Pareja M, Ayuso-Peralta L, et al. Drug-induced parkinsonism in a movement disorders unit: a four years survey. Parkinsonism Relat Disord 1996;2:145-149.
6. Errea Abad JM, Ara-Callizo JR, Aibar-Remón C. Parkinsonismo inducido por fármacos: aspectos clínicos comparativos con la enfermedad de Parkinson. Rev Neurol 1998;27:35-39.
7. Vázquez-Alen P, Pérez-Gilabert Y, Mateo D, et al. Estudio sobre una base de datos de 2.471 pacientes con enfermedad de Parkinson y trastornos del movimiento en el Area Sanitaria 1 de la Comunidad de Madrid. Cambios demograficos observados a lo largo de ocho años. Rev Neurol 2000;30:635-640.
8. Ortí-Pareja M, Jiménez-Jiménez FJ, Vázquez A, et al. Grupo Centro de Trastornos del Movimiento. Drug-induced tardive syndromes. Parkinsonism Relat Disord 1999;5:59-65.
9. Fabiani G, Pastro PC, Froehner C. Parkinsonism and other movement disorders in outpatients in chronic use of cinnarizine and flunarizine. Arq Neuropsiquiatr 2004;62:784-788.
10. García-Ruiz PJ, Mena MA, Peñafiel N, et al. Cinnarizine-induced parkinsonism in primates. Clin Neuropharmacol 1992;15:152-154.
11. Mena MA, García de Yébenes MJ, Tabernero C, et al. Effects of calcium antagonists on the dopamine system. Clin Neuropharmacol 1995;18:410-426.
12. Serrano A, Menéndez J, Casarejos MJ, et al. Effects of cinnarizine, a calcium antagonist that produces human parkinsonism, in parkin knock out mice. Neuropharmacology 2005;49:208-219.
13. Paton DM, Webster DR. Clinical pharmacokinetics of H1-receptor antagonists (the antihistamines). Clin Pharmacokinet 1985;10:477-497.
14. Sachdev P. Tardive blepharospasm. Mov Disord 1998;13:947-951.
15. Burke RE, Fahn S, Jankovic J, et al. Tardive dystonia: late onset and persistent dystonia caused by antipsychotic drugs. Neurology 1982;32:1335-1346.
16. Grandas F, Elston J, Quinn N, et al. Blepharospasm: a review of 264 patients. J Neurol Neurosurg Psychiatry 1988;51:767-772.
17. Weiner WJ, Nausieda PA, Glantz RH. Meige syndrome (blepharospasm- oromandibular dystonia) after long-term neuroleptic therapy. Neurology 1981;31:1555-1556.
18. Ananth J, Edelmuth E, Dargan B. Meige's syndrome associated with neuroleptic medication. Am J Psychiatry 1988;145:513-515.
19. Dilsaver SC, Domino L, Greden JF. Meige's syndrome to tardive dyskinesia. J Clin Psychopharmacol 1985;5:362-364.
20. Kurata K, Yuasa S, Kazukawa S, et al. Meige's syndrome during long-term neuroleptic treatment. Jpn J Psychiatry Neurol 1989;43:627-631.
21. Van Putten T, Wirshing WC, Marder SR. Tardive Meige syndrome responsive to clozapine. J Clin Psychopharmacol 1990;10:381-382.
22. Santi CM, Cayabyab FS, Sutton KG, et al. Differential inhibition of T-type calcium channels by neuroleptics. J Neurosci 2002;22:396-403.
23. Antkiewicz-Michaluk L, Karolewicz B, Michaluk J, et al. Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. Eur J Pharmacol 1995;294:459-467.
24. Koukoulis A, Herrero JS, Gómez-Alonso J. Blepharospasm induced by flunarizine. J Neurol Neurosurg Psychiatry 1997;63:412-413.
25. Micheli FE, Fernández-Pardal MM, Giannaula R, et al. Movement disorders and depression due to flunarizine and cinnarizine. Mov Disord 1989;4:139-146.